Healthcare entity
Each story carries 2.3 original sources on average, compared with 3.5 for the broader beat in this window. Pfizer is the most frequent co-covered peer, appearing in 3 of the 7 tracked stories. Across a 165-day span, the pace is roughly 0.3 stories per week.
Last mentioned: Aug 20, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 14 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Each story carries 2.3 original sources on average, compared with 3.5 for the broader beat in this window. Pfizer is the most frequent co-covered peer, appearing in 3 of the 7 tracked stories. Across a 165-day span, the pace is roughly 0.3 stories per week. Negative sentiment reaches 14% here, compared with 25% across the 927-story beat baseline for the same window. At 6.6, the average consequence score sits above the same-window beat average of 6. The clearest coverage concentration is market-trends: 4 of 7 stories, with the rest divided among 3 other categories. This profile follows 7 Healthcare stories mentioning Bristol Myers Squibb across the period from March 9, 2026 to August 20, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 927 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bristol Myers Squibb. Shared-story counts are live from our verified record — not editorial picks.
DCAT Week 2026
LOTTE Biologics engages in high-level partnership talks in New York City.
ADC Expansion
Completion of specialized ADC manufacturing lines at the Syracuse facility.
Songdo Groundbreaking
Construction begins on the first Mega Plant in Songdo, South Korea.
Syracuse Acquisition
LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.
A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
The potential combination of two pharmaceutical powerhouses would concentrate ownership of critical cardiovascular and oncology treatments, raising concerns about pricing power, NHS supply chains, and worldwide health equity.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Source: The Motley Fool · fool.com
Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Source: tickerreport.com · dailypolitical.com
New research indicates that patients with Mild Cognitive Impairment (MCI) and dementia are at a significantly higher risk for developing cardiovascular conditions requiring anticoagulants. This finding underscores the clinical challenge of managing stroke prevention in cognitively impaired populations with high fall risks.
Source: psychiatryadvisor.com · neurologyadvisor.com
LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.
Source: singaporestar.com · cambodiantimes.com
Bristol Myers Squibb is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
